Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases

Cancer

Volumn 117, Issue 15, 2011, Pages 3457-3467

  Koshkina, Nadezhda V ^a   Rao Bindal, Krithi ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

aerosol; apoptosis; Fas; histone deacetylase inhibitor; lung metastasis; osteosarcoma

Indexed keywords

ENTINOSTAT; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEASIBILITY STUDY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIGENS, CD95; BASE SEQUENCE; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; FEASIBILITY STUDIES; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C3H; MICE, NUDE; OSTEOSARCOMA; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 79960698626     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25884     Document Type: Article

References (34)

1. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008; 17: 1703-1715.
2. Sartorius U, Schmitz I, Krammer PH., Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem. 2001; 2: 20-29.
3. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES., Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007; 5: 991-999. (Pubitemid 350070755)
4. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005; 27: 611-615. (Pubitemid 41697350)
5. Koshkina NV, Kleinerman ES., Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005; 116: 458-463. (Pubitemid 40993344)
6. Gordon N, Koshkina NV, Jia SF, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007; 13 (15 pt 1): 4503-4510. (Pubitemid 47219720)
7. Imai T, Adachi S, Nishijo K, et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene. 2003; 22: 9231-9242. (Pubitemid 38122035)
8. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008; 409: 581-589. (Pubitemid 351184977)
9. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999; 96: 4592-4597. (Pubitemid 29190381)
10. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002; 62: 6108-6115. (Pubitemid 35244459)
11. Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B, Hess-Stumpp H., Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol. 2009; 35: 909-920.
12. Khandelwal A, Gediya L, Njar V., MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer. 2008; 98: 1234-1243. (Pubitemid 351481680)
13. Jia SF, Worth LL, Kleinerman ES., A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999; 17: 501-506. (Pubitemid 30182744)
14. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 1998; 76: 418-422. (Pubitemid 28282943)
15. Koshkina NV, Kleinerman ES, Waidrep C, et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000; 6: 2876-2880. (Pubitemid 30482130)
16. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V., Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001; 7: 3258-3262. (Pubitemid 32963851)
17. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004; 10: 2319-2326. (Pubitemid 38445689)
18. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, Parodi B., Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res. 2009; 37 (database issue): D925-D932.
19. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB., Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3. Prostate. 2002; 51: 231-240. (Pubitemid 34556373)
20. Zhang J, Winoto A., A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol. 1996; 16: 2756-2763.
21. Bebenek M, Dus D, Kozlak J., Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res. 2007; 27 (1A): 215-218. (Pubitemid 46363334)
22. Onodera H, Mori A, Nagayama S, et al. Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer. Int J Colorectal Dis. 2005; 20: 477-484. (Pubitemid 41479014)
23. Asensio C, Zapata A, Garcia-Ahijado J, Gil B, Salvadores P, Schneider J., Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. Anticancer Res. 2007; 27 (6B): 4083-4086.
24. Huang G, Koshkina NV, Kleinerman ES., Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncol Res. 2009; 18: 31-39.
25. Escaffit F, Vaute O, Chevillard-Briet M, et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol. 2007; 27: 554-567. (Pubitemid 46080124)
26. Kim HR, Kim EJ, Yang SH, et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp Mol Med. 2006; 38: 616-624.
27. Wood TE, Dalili S, Simpson CD, et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010; 9: 246-256.
28. Watanabe K, Okamoto K, Yonehara S., Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through down-regulation of cellular FLIP. Cell Death Differ. 2005; 12: 10-18. (Pubitemid 40090024)
29. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE., Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res. 2008; 6: 873-883.
30. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC., Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006; 66: 1277-1281. (Pubitemid 43259904)
31. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009; 125: 2737-2743.
32. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J., Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006; 26: 2019-2028. (Pubitemid 43346906)
33. Jung ID, Lee JS, Jeong YI, et al. Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int J Immunopathol Pharmacol. 2009; 22: 501-515.
34. Watanabe M, Adachi S, Matsubara H, et al. Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation. Int J Cancer. 2009; 124: 55-67.